NEW YORK — It’s not really a stretch of the imagination to think that microbiome companies should care deeply about who will lead the Food and Drug Administration after the current commissioner, Scott Gottlieb, departs in a few weeks. After all, no microbiome-based drug has yet gone through the regulatory process and made it to market and investors are still skittish about how those drugs will be received by the agency.
Yet a five-person panel of microbiome executives on a panel at the inaugural Chardan Microbiome Summit on Thursday didn’t address the shift in leadership until prompted by a member of the audience. And when they did, the response was essentially “meh.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
signed up for 30 day free trial and still can’t get the article even after logging in